What is the main business of Purevibe Science?

The main business activity of Purevibe Science focuses on manufacture of pharmaceutical preparations.

When was the company founded?

The company was registered in the Polish National Court Register (KRS) on October 17, 2024.

Where is the headquarters located?

The headquarters is located at: ul. Chabrowa 4, 52-200 Wysoka.

What is the share capital?

The share capital of the company is PLN 10,000 (approx. $2,701).

What period do the latest financial data cover?

The latest available financial statement covers the period from October 17, 2024 to December 31, 2025.

What revenue was generated?

In 2025, the company's revenue reached $76,653.

Yes, in 2025 the company was profitable, achieving a net profit of $9,308.

Which cost dominates operating expenses?

The largest operating cost category falls under external services. This category amounted to $65,974 in 2025, representing 99% of all operating expenses.

Purevibe Sciencesp. z o.o.

Manufacture of pharmaceutical preparations

KRS: NIP: REGON:

Overview

Status

Active

Registry date

2024-10-17

Share capital

10,000.00 PLN

Registered address

ul. Chabrowa 4, 52-200 Wysoka, Poland

Financials

From the notes

Current income tax (CIT due)

$924

Filing timeliness

The financial statement for 2025 was filed on time.

202530/04/2026

Filed on timeDelayFiling deadline

Data and insights are generated automatically from financial statements – they may contain errors and are neither a credit assessment nor business advice.

Statistics

How the company ranks by revenue within its industry, city, voivodeship and across Poland in 2025.

Industry · Manufacture of pharmaceutical preparations143 / 184

Top 78%

Division · Manufacture of basic pharmaceutical products and pharmaceutical preparations176 / 231

Top 76%

Sector · Manufacturing20,060 / 24,479

Top 82%

City · Wysoka49 / 67

Top 73%

Voivodeship · Dolnośląskie16,411 / 23,907

Top 69%

Country · Poland205,444 / 297,935

Top 69%

Results vs industry

Revenue

This companyUSD 76.65kMedianUSD 919.05kAverageUSD 25.83m

Net profit

This companyUSD 9.31kMedianUSD 14.92kAverageUSD 2.77m

Operating costs

This companyUSD 66.39kMedianUSD 873.06kAverageUSD 21.43m

Assets

This companyUSD 12.89kMedianUSD 897.46kAverageUSD 31.52m

Industry

Manufacture of pharmaceutical preparations (21.20.Z)Primary
Manufacture of soap and detergents, cleaning and polishing preparations, perfumes and (20.4)
Manufacture of basic pharmaceutical products and pharmaceutical preparations (21)

Authorized Representatives

Piotr Marcin Tyliński – President of the Management Board

Manner of representation

In the case of a one-person management board, the company is represented by one member of the management board. In the case of a multi-member management board of the company, the company is represented by two members of the management board acting jointly, or by one member of the management board acting jointly with a commercial proxy.

Ownership

Owner	Shares	Share value	Stake
Piotr Marcin Tylińskiage 50	100	$2,701.24	100%

Beneficial owners

Person	Rights

Bank accounts

Registered as a VAT taxpayer on 2024-12-01.

Erste Bank Polska
59 1090 2590 0000 0001 6016 5044

Debt

No entries in the National Debtors Register (KRZ).

Public aid

No public aid cases recorded in the last 10 years.

Competitors

Name	Revenue	Website
Przedsiębiorstwo Produkcji Farmaceutycznej Hasco - LekS.A.	$119,621,017.71	hasco-lek.pl
Wrocławskie Zakłady Zielarskie HerbapolS.A.	$46,537,868.51	herbapol.pl
Labor Przedsiębiorstwo Farmaceutyczno - Chemicznesp. z o.o.	$1,184,204.34	labor.com.pl
Zeptor Polskasp. z o.o.	$748,374.79	zeptor.pl
STEM Cells SpinS.A.	$287,714.76	stemcellsspin.com.pl
LideoS.A.	$95,067.91	lideo.tech
Munar PharmaS.A.	$85,649.72	munar.pl
BIO Animalisp. z o.o.	$49,176.96	proanimali.com
Ampliconsp. z o.o.	$48,330.99	amplicon.pl
Xenira Pharmaceuticalssp. z o.o.	$26,670.82	xenirapharma.com